That’s what we are trying to explain to the physician’s community. It’s anemia with signs of hemolysis, with a negative Coombs test, it’s important. It’s unusual thrombosis in angiocytes in younger patients below 40. And that’s what we have in our guidelines. In all patients who have thrombosis at an age below 40, they should be screened for PNH...
That’s what we are trying to explain to the physician’s community. It’s anemia with signs of hemolysis, with a negative Coombs test, it’s important. It’s unusual thrombosis in angiocytes in younger patients below 40. And that’s what we have in our guidelines. In all patients who have thrombosis at an age below 40, they should be screened for PNH. And we have some cytopenia which is not so usual and we can exclude MDS probably. Those are all the candidates for PNH treatment. And I think these are the basic diagnostic things. To my mind, it’s important that these patients should be screened by flow cytometry for PNH because it’s not a difficult investigation. You have peripheral blood and it’s not very expensive. So it’s an exact diagnosis of PNH, so all these patients should be screened. Better more than less.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.